330 related articles for article (PubMed ID: 17614877)
1. Regulation of ligands for the activating receptor NKG2D.
Mistry AR; O'Callaghan CA
Immunology; 2007 Aug; 121(4):439-47. PubMed ID: 17614877
[TBL] [Abstract][Full Text] [Related]
2. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
[TBL] [Abstract][Full Text] [Related]
3. NKG2D ligands: key targets of the immune response.
González S; López-Soto A; Suarez-Alvarez B; López-Vázquez A; López-Larrea C
Trends Immunol; 2008 Aug; 29(8):397-403. PubMed ID: 18602338
[TBL] [Abstract][Full Text] [Related]
4. The NKG2D receptor: sensing stressed cells.
López-Larrea C; Suárez-Alvarez B; López-Soto A; López-Vázquez A; Gonzalez S
Trends Mol Med; 2008 Apr; 14(4):179-89. PubMed ID: 18353724
[TBL] [Abstract][Full Text] [Related]
5. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.
Doubrovina ES; Doubrovin MM; Vider E; Sisson RB; O'Reilly RJ; Dupont B; Vyas YM
J Immunol; 2003 Dec; 171(12):6891-9. PubMed ID: 14662896
[TBL] [Abstract][Full Text] [Related]
6. Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity.
Dunn C; Chalupny NJ; Sutherland CL; Dosch S; Sivakumar PV; Johnson DC; Cosman D
J Exp Med; 2003 Jun; 197(11):1427-39. PubMed ID: 12782710
[TBL] [Abstract][Full Text] [Related]
7. Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin.
Pende D; Cantoni C; Rivera P; Vitale M; Castriconi R; Marcenaro S; Nanni M; Biassoni R; Bottino C; Moretta A; Moretta L
Eur J Immunol; 2001 Apr; 31(4):1076-86. PubMed ID: 11298332
[TBL] [Abstract][Full Text] [Related]
8. NKG2D-mediated cytotoxicity toward oligodendrocytes suggests a mechanism for tissue injury in multiple sclerosis.
Saikali P; Antel JP; Newcombe J; Chen Z; Freedman M; Blain M; Cayrol R; Prat A; Hall JA; Arbour N
J Neurosci; 2007 Jan; 27(5):1220-8. PubMed ID: 17267578
[TBL] [Abstract][Full Text] [Related]
9. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein.
Rölle A; Mousavi-Jazi M; Eriksson M; Odeberg J; Söderberg-Nauclér C; Cosman D; Kärre K; Cerboni C
J Immunol; 2003 Jul; 171(2):902-8. PubMed ID: 12847260
[TBL] [Abstract][Full Text] [Related]
10. Role of NK cell-activating receptors and their ligands in the lysis of mononuclear phagocytes infected with an intracellular bacterium.
Vankayalapati R; Garg A; Porgador A; Griffith DE; Klucar P; Safi H; Girard WM; Cosman D; Spies T; Barnes PF
J Immunol; 2005 Oct; 175(7):4611-7. PubMed ID: 16177106
[TBL] [Abstract][Full Text] [Related]
11. T cells gene-engineered with DAP12 mediate effector function in an NKG2D-dependent and major histocompatibility complex-independent manner.
Teng MW; Kershaw MH; Hayakawa Y; Cerutti L; Jane SM; Darcy PK; Smyth MJ
J Biol Chem; 2005 Nov; 280(46):38235-41. PubMed ID: 16169855
[TBL] [Abstract][Full Text] [Related]
12. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity.
Diefenbach A; Jensen ER; Jamieson AM; Raulet DH
Nature; 2001 Sep; 413(6852):165-71. PubMed ID: 11557981
[TBL] [Abstract][Full Text] [Related]
13. Immunobiology of human NKG2D and its ligands.
González S; Groh V; Spies T
Curr Top Microbiol Immunol; 2006; 298():121-38. PubMed ID: 16329186
[TBL] [Abstract][Full Text] [Related]
14. Transfer of NKG2D and MICB at the cytotoxic NK cell immune synapse correlates with a reduction in NK cell cytotoxic function.
Roda-Navarro P; Vales-Gomez M; Chisholm SE; Reyburn HT
Proc Natl Acad Sci U S A; 2006 Jul; 103(30):11258-63. PubMed ID: 16849432
[TBL] [Abstract][Full Text] [Related]
15. NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation.
Gilfillan S; Ho EL; Cella M; Yokoyama WM; Colonna M
Nat Immunol; 2002 Dec; 3(12):1150-5. PubMed ID: 12426564
[TBL] [Abstract][Full Text] [Related]
16. An activating immunoreceptor complex formed by NKG2D and DAP10.
Wu J; Song Y; Bakker AB; Bauer S; Spies T; Lanier LL; Phillips JH
Science; 1999 Jul; 285(5428):730-2. PubMed ID: 10426994
[TBL] [Abstract][Full Text] [Related]
17. Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors.
Bryceson YT; Ljunggren HG; Long EO
Blood; 2009 Sep; 114(13):2657-66. PubMed ID: 19628705
[TBL] [Abstract][Full Text] [Related]
18. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages.
Diefenbach A; Jamieson AM; Liu SD; Shastri N; Raulet DH
Nat Immunol; 2000 Aug; 1(2):119-26. PubMed ID: 11248803
[TBL] [Abstract][Full Text] [Related]
19. The NKG2D receptor: immunobiology and clinical implications.
Burgess SJ; Maasho K; Masilamani M; Narayanan S; Borrego F; Coligan JE
Immunol Res; 2008; 40(1):18-34. PubMed ID: 18193361
[TBL] [Abstract][Full Text] [Related]
20. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells.
Sutherland CL; Chalupny NJ; Schooley K; VandenBos T; Kubin M; Cosman D
J Immunol; 2002 Jan; 168(2):671-9. PubMed ID: 11777960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
